已收盘 09-19 16:00:00 美东时间
+0.100
+6.13%
Compass Therapeutics (NASDAQ:CMPS) filed for $300M mixed securities shelf. Filing More on COMPASS Pathways ADS Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision Psychedel...
08-31 05:31
Compass Therapeutics Inc. : Leerink Partners Cuts Target Price to $5 From $10
08-13 10:46
Compass Therapeutics press release (NASDAQ:CMPX): Q2 GAAP EPS of -$0.10. Revenue of $0.85M. More on Compass Therapeutics Compass Therapeutics: Pointing Right At Some Tough Cancers Compass Therapeutics...
08-12 21:06
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 11.11 percent decrease over losses of $(0.09) per share from the same period last
08-12 20:11
Compass Therapeutics Q2 Operating Expenses USD 15.895 Million
08-12 20:01
Compass Therapeutics Q2 Net Income USD -13.076 Million
08-12 20:01
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides...
08-12 20:01
Compass Therapeutics Q2 Income From Operations USD -15.045 Million
08-12 20:01
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Seeking Alpha's earnings calendar for a full list of companies due to report....
08-10 03:00